Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat reports. Two ...
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
Inc. has seen its stock tumble to a 52-week low, touching down at $1.12. With a current market capitalization of just $93 million, the company maintains a strong liquidity position with a current ...
The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and mainly be driven by an increase in approval of a ...
Check Out Our Latest Stock Analysis on EDIT Editas Medicine Trading Down 2.1 % NASDAQ:EDIT opened at $1.38 on Friday. The company has a market capitalization of $113.92 million, a P/E ratio of -0. ...
Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results